Construction of a nomogram for predicting HNSCC distant metastasis and identification of EIF5A as a hub gene.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
11 Jun 2024
Historique:
received: 07 01 2024
accepted: 06 06 2024
medline: 12 6 2024
pubmed: 12 6 2024
entrez: 11 6 2024
Statut: epublish

Résumé

Patients with distant metastasis of head and neck squamous cell carcinoma (HNSCC) often have a poor prognosis. However, early diagnosis of distant metastasis is challenging in clinical practice, and distant metastasis is often only detected in the late stages of tumor metastasis through imaging techniques. In this study, we utilized data from HNSCC patients collected from the TCGA database. Patients were divided into distant metastasis and nonmetastasis groups based on the tumor-node-metastasis (TNM) stage. We analyzed the differentially expressed genes between the two groups (DM/non-M DEGs) and their associated lncRNAs and generated a predictive model based on 23 lncRNAs that were significantly associated with the occurrence of distant metastasis in HNSCC patients. On this basis, we built a nomogram to predict the distant metastasis of HNSCC patients. Moreover, through WGCNA and Cytoscape software analysis of DM/non-M DEGs, we identified the gene most closely related to HNSCC distant metastasis: EIF5A. Our findings were validated using GEO data; EIF5A expression was significantly increased in the tumor tissues of HNSCC patients with distant metastasis. We then predicted miRNAs that can directly bind to EIF5A via the TargetScan and miRWalk websites, intersected them with differentially expressed miRNAs in the two groups from the TCGA cohort, and identified the only overlapping miRNA, miR-424; we predicted the direct binding site of EIF5A and miR-424 via the miRWalk website. Immunohistochemistry further revealed high expression of EIF5A in the primary tumor tissue of HNSCC patients with distant metastasis. These results provide a new perspective for the early diagnosis of distant metastasis in HNSCC patients and the study of the mechanisms underlying HNSCC distant metastasis.

Identifiants

pubmed: 38862693
doi: 10.1038/s41598-024-64197-z
pii: 10.1038/s41598-024-64197-z
doi:

Substances chimiques

Peptide Initiation Factors 0
RNA-Binding Proteins 0
Eukaryotic Translation Initiation Factor 5A 0
MicroRNAs 0
RNA, Long Noncoding 0
Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

13367

Informations de copyright

© 2024. The Author(s).

Références

Johnson, D. E. et al. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Primers 6, 92. https://doi.org/10.1038/s41572-020-00224-3 (2020).
doi: 10.1038/s41572-020-00224-3 pubmed: 33243986 pmcid: 7944998
Bugshan, A. & Farooq, I. Oral squamous cell carcinoma: metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. F1000Res 9, 229. https://doi.org/10.12688/f1000research.22941.1 (2020).
doi: 10.12688/f1000research.22941.1 pubmed: 32399208 pmcid: 7194458
Kunieda, F. et al. Randomized phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck: Japan Clinical Oncology Group Study (JCOG1008). Jpn. J. Clin. Oncol. 44, 770–774. https://doi.org/10.1093/jjco/hyu067 (2014).
doi: 10.1093/jjco/hyu067 pubmed: 24842866
Lau, A., Yang, W. F., Li, K. Y. & Su, Y. X. Systemic therapy in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 153, 102984. https://doi.org/10.1016/j.critrevonc.2020.102984 (2020).
doi: 10.1016/j.critrevonc.2020.102984 pubmed: 32569853
Elmusrati, A., Wang, J. & Wang, C. Y. Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. Int. J. Oral Sci. 13, 24. https://doi.org/10.1038/s41368-021-00131-7 (2021).
doi: 10.1038/s41368-021-00131-7 pubmed: 34341329 pmcid: 8329257
Gerstberger, S., Jiang, Q. & Ganesh, K. Metastasis. Cell 186, 1564–1579. https://doi.org/10.1016/j.cell.2023.03.003 (2023).
doi: 10.1016/j.cell.2023.03.003 pubmed: 37059065 pmcid: 10511214
Suhail, Y. et al. Systems biology of cancer metastasis. Cell Syst. 9, 109–127. https://doi.org/10.1016/j.cels.2019.07.003 (2019).
doi: 10.1016/j.cels.2019.07.003 pubmed: 31465728 pmcid: 6716621
Klein, C. A. Cancer progression and the invisible phase of metastatic colonization. Nat. Rev. Cancer 20, 681–694. https://doi.org/10.1038/s41568-020-00300-6 (2020).
doi: 10.1038/s41568-020-00300-6 pubmed: 33024261
Fares, J., Fares, M. Y., Khachfe, H. H., Salhab, H. A. & Fares, Y. Molecular principles of metastasis: A hallmark of cancer revisited. Signal Transduct. Target Ther. 5, 28. https://doi.org/10.1038/s41392-020-0134-x (2020).
doi: 10.1038/s41392-020-0134-x pubmed: 32296047 pmcid: 7067809
Castro-Giner, F. & Aceto, N. Tracking cancer progression: From circulating tumor cells to metastasis. Genome Med. 12, 31. https://doi.org/10.1186/s13073-020-00728-3 (2020).
doi: 10.1186/s13073-020-00728-3 pubmed: 32192534 pmcid: 7082968
Stoletov, K., Beatty, P. H. & Lewis, J. D. Novel therapeutic targets for cancer metastasis. Expert Rev. Anticancer Ther. 20, 97–109. https://doi.org/10.1080/14737140.2020.1718496 (2020).
doi: 10.1080/14737140.2020.1718496 pubmed: 31997674
Osman, A. A. et al. Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in head and neck squamous cell carcinoma. Clin. Cancer Res. 29, 1344–1359. https://doi.org/10.1158/1078-0432.Ccr-22-2747 (2023).
doi: 10.1158/1078-0432.Ccr-22-2747 pubmed: 36689560 pmcid: 10068451
Zhang, M. et al. FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program. Mol. Ther. 29, 2583–2600. https://doi.org/10.1016/j.ymthe.2021.03.024 (2021).
doi: 10.1016/j.ymthe.2021.03.024 pubmed: 33794365 pmcid: 8353207
Lyden, D. et al. Metastasis. Cancer Cell 40, 787–791. https://doi.org/10.1016/j.ccell.2022.07.010 (2022).
doi: 10.1016/j.ccell.2022.07.010 pubmed: 35944497 pmcid: 9924435
Massagué, J. & Ganesh, K. Metastasis-initiating cells and ecosystems. Cancer Discov. 11, 971–994. https://doi.org/10.1158/2159-8290.Cd-21-0010 (2021).
doi: 10.1158/2159-8290.Cd-21-0010 pubmed: 33811127 pmcid: 8030695
Vaghari-Tabari, M. et al. Signaling, metabolism, and cancer: An important relationship for therapeutic intervention. J. Cell Physiol. 236, 5512–5532. https://doi.org/10.1002/jcp.30276 (2021).
doi: 10.1002/jcp.30276 pubmed: 33580511
Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587-d592. https://doi.org/10.1093/nar/gkac963 (2023).
doi: 10.1093/nar/gkac963 pubmed: 36300620
Filip, S. et al. Distant metastasis in colorectal cancer patients-do We have new predicting clinicopathological and molecular biomarkers? A comprehensive review. Int. J. Mol. Sci. 21, 255. https://doi.org/10.3390/ijms21155255 (2020).
doi: 10.3390/ijms21155255
Zhang, Y. et al. A population-based analysis of distant metastasis in stage IV gastric cancer. Med. Sci. Monit. 26, e923867. https://doi.org/10.12659/msm.923867 (2020).
doi: 10.12659/msm.923867 pubmed: 32409630 pmcid: 7245058
Shao, Y. et al. Distant metastasis in medullary thyroid carcinoma: Clinical outcomes and implications of T stage. Clin. Endocrinol. (Oxf.) 97, 676–684. https://doi.org/10.1111/cen.14717 (2022).
doi: 10.1111/cen.14717 pubmed: 35261045
Ding, Y., Li, P., Wang, W. & Liu, F. A potential four-gene signature and nomogram for predicting the overall survival of papillary thyroid cancer. Dis. Mark. 2022, 8735551. https://doi.org/10.1155/2022/8735551 (2022).
doi: 10.1155/2022/8735551
Li, Y. et al. Long non-coding RNA ENST00000503625 is a potential prognostic biomarker and metastasis suppressor gene in prostate cancer. J. Cancer Res. Clin. Oncol. 149, 7305–7317. https://doi.org/10.1007/s00432-023-04676-4 (2023).
doi: 10.1007/s00432-023-04676-4 pubmed: 36920562
Fang, C. et al. Development and validation of a clinical prediction model for the risk of distal metastasis in intrahepatic cholangiocarcinoma: a real-world study. BMC Gastroenterol. 24, 1. https://doi.org/10.1186/s12876-023-03084-9 (2024).
doi: 10.1186/s12876-023-03084-9 pubmed: 38166611 pmcid: 10759461
Ali, M., Mumtaz, M., Naqvi, Z., Farooqui, R. & Shah, S. A. Assessing tumor size by MRI and pathology in type I endometrial carcinoma to predict lymph node metastasis. Cureus 14, e23135. https://doi.org/10.7759/cureus.23135 (2022).
doi: 10.7759/cureus.23135 pubmed: 35444870 pmcid: 9009998
Li, J. et al. HSPA5, as a ferroptosis regulator, may serve as a potential therapeutic for head and neck squamous cell carcinoma. Mol. Immunol. 158, 79–90. https://doi.org/10.1016/j.molimm.2023.05.001 (2023).
doi: 10.1016/j.molimm.2023.05.001 pubmed: 37172353
Peng, J. M. & Su, Y. L. Lymph node metastasis and tumor-educated immune tolerance: Potential therapeutic targets against distant metastasis. Biochem. Pharmacol. 215, 115731. https://doi.org/10.1016/j.bcp.2023.115731 (2023).
doi: 10.1016/j.bcp.2023.115731 pubmed: 37541450
Joshi, K. et al. Macroscopic extranodal extension in oral squamous cell carcinoma: A subgroup with poor survival. Laryngoscope 133, 588–593. https://doi.org/10.1002/lary.30158 (2023).
doi: 10.1002/lary.30158 pubmed: 35567419
Barba-Aliaga, M. & Alepuz, P. Role of EIF5A in mitochondrial function. Int. J. Mol. Sci. 23, 1284. https://doi.org/10.3390/ijms23031284 (2022).
doi: 10.3390/ijms23031284 pubmed: 35163207 pmcid: 8835957
Seoane, R. et al. EIF5A is activated by virus infection or dsRNA and facilitates virus replication through modulation of interferon production. Front. Cell Infect. Microbiol. 12, 960138. https://doi.org/10.3389/fcimb.2022.960138 (2022).
doi: 10.3389/fcimb.2022.960138 pubmed: 35967877 pmcid: 9363599
Martella, M. et al. Inhibition of eukaryotic translation initiation factor 5A (EIF5A) hypusination suppress p53 translation and alters the association of EIF5A to the ribosomes. Int. J. Mol. Sci. 21, 583. https://doi.org/10.3390/ijms21134583 (2020).
doi: 10.3390/ijms21134583
Tan, T. C. J. et al. Translation factor EIF5A is essential for IFNγ production and cell cycle regulation in primary CD8(+) T lymphocytes. Nat. Commun. 13, 7796. https://doi.org/10.1038/s41467-022-35252-y (2022).
doi: 10.1038/s41467-022-35252-y pubmed: 36528626 pmcid: 9759561
Fujimura, K. et al. Eukaryotic translation initiation factor 5A (EIF5A) regulates pancreatic cancer metastasis by modulating RhoA and rho-associated kinase (ROCK) protein expression levels. J. Biol. Chem. 290, 29907–29919. https://doi.org/10.1074/jbc.M115.687418 (2015).
doi: 10.1074/jbc.M115.687418 pubmed: 26483550 pmcid: 4706006
Zhu, W. et al. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition. Gut 61, 562–575. https://doi.org/10.1136/gutjnl-2011-300207 (2012).
doi: 10.1136/gutjnl-2011-300207 pubmed: 21813470
Tunca, B. et al. Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients. J. Cancer Res. Clin. Oncol. 139, 691–702. https://doi.org/10.1007/s00432-013-1372-x (2013).
doi: 10.1007/s00432-013-1372-x pubmed: 23322277
He, L. R. et al. Overexpression of EIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients. Int. J. Cancer 129, 143–150. https://doi.org/10.1002/ijc.25669 (2011).
doi: 10.1002/ijc.25669 pubmed: 20830705
Zeng, J. et al. Targeted inhibition of EIF5A(hpu) suppresses tumor growth and polarization of M2-like tumor-associated macrophages in oral cancer. Cell Death Dis. 14, 579. https://doi.org/10.1038/s41419-023-06109-z (2023).
doi: 10.1038/s41419-023-06109-z pubmed: 37653021 pmcid: 10471704
Kim, S. M., Jeong, D., Kim, M. K., Lee, S. S. & Lee, S. K. Two different protein expression profiles of oral squamous cell carcinoma analyzed by immunoprecipitation high-performance liquid chromatography. World J. Surg. Oncol. 15, 151. https://doi.org/10.1186/s12957-017-1213-5 (2017).
doi: 10.1186/s12957-017-1213-5 pubmed: 28789700 pmcid: 5549376
Dastmalchi, N., Safaralizadeh, R. & Banan Khojasteh, S. M. The correlation between microRNAs and Helicobacter pylori in gastric cancer. Pathog. Dis. 77, 39. https://doi.org/10.1093/femspd/ftz039 (2019).
doi: 10.1093/femspd/ftz039
Azarbarzin, S., Feizi, M. A. H., Safaralizadeh, R., Kazemzadeh, M. & Fateh, A. The value of MiR-383, an intronic MiRNA, as a diagnostic and prognostic biomarker in intestinal-type gastric cancer. Biochem. Genet. 55, 244–252. https://doi.org/10.1007/s10528-017-9793-x (2017).
doi: 10.1007/s10528-017-9793-x pubmed: 28243881
Mollaei, H., Safaralizadeh, R. & Rostami, Z. MicroRNA replacement therapy in cancer. J. Cell Physiol. 234, 12369–12384. https://doi.org/10.1002/jcp.28058 (2019).
doi: 10.1002/jcp.28058 pubmed: 30605237
Li, N. CircTBL1XR1/miR-424 axis regulates Smad7 to promote the proliferation and metastasis of colorectal cancer. J. Gastrointest. Oncol. 11, 918–931. https://doi.org/10.21037/jgo-20-395 (2020).
doi: 10.21037/jgo-20-395 pubmed: 33209488 pmcid: 7657834
Chen, Q. et al. Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription. J. Hepatol. 76, 135–147. https://doi.org/10.1016/j.jhep.2021.08.027 (2022).
doi: 10.1016/j.jhep.2021.08.027 pubmed: 34509526
Scholtz, B., Horváth, J., Tar, I., Kiss, C. & Márton, I. J. Salivary miR-31-5p, miR-345-3p, and miR-424-3p are reliable biomarkers in patients with oral squamous cell carcinoma. Pathogens https://doi.org/10.3390/pathogens11020229 (2022).
doi: 10.3390/pathogens11020229 pubmed: 35215172 pmcid: 8876825
Gong, Z. et al. A novel circular RNA circRBMS3 regulates proliferation and metastasis of osteosarcoma by targeting miR-424-eIF4B/YRDC axis. Aging (Albany NY) 15, 1564–1590. https://doi.org/10.18632/aging.204567 (2023).
doi: 10.18632/aging.204567 pubmed: 36897170

Auteurs

Xin Chen (X)

Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China.

Ying Zhang (Y)

Oncology Department, The Second Hospital of Nanjing, Nanjing, China.

Sheng Chen (S)

Department of Oral Pathology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China.

Yan Yang (Y)

Department of Oral Pathology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China.

Guowen Sun (G)

Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China. guowensun@nju.edu.cn.

Peng Pan (P)

Department of Clinical Laboratory, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China. jerry0727@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH